Recent progress in the management of atherosclerosis and hyperlipidemia
Despite the positive trend over the last decade, mortality from the circulatory system diseases in the Russian Federation remains high: in 2016, 616 cases per 100 thousand people were registered, with an absolute loss of about 900 thousand people, of whom nearly 50% died from coronary artery disease...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2017-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/1762 |
id |
doaj-18581cd2b53f4396b5ad78abf85e7d50 |
---|---|
record_format |
Article |
spelling |
doaj-18581cd2b53f4396b5ad78abf85e7d502021-07-28T13:29:32ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902017-12-010751010.21518/2079-701X-2017-7-5-101744Recent progress in the management of atherosclerosis and hyperlipidemiaM. V. Ezhov0Research Institute of Clinical Cardiology named after A.L. Myasnikov, Russian Cardiology Research and Production ComplexDespite the positive trend over the last decade, mortality from the circulatory system diseases in the Russian Federation remains high: in 2016, 616 cases per 100 thousand people were registered, with an absolute loss of about 900 thousand people, of whom nearly 50% died from coronary artery disease (CAD). Atherosclerosis plays a critical role in the development of cardiovascular disease, as the damage to the arterial bed begins early - already at a young age. The major modifiable risk factors for atherosclerosis are hyperlipidemia, hypertension, diabetes, smoking. The leading risk factor for coronary atherosclerosis is lowdensity lipoprotein cholesterol (LDL-C). According to EUROASPIRE III, in Russia, hypercholesterolemia is found in 65% of patients with CAD (LDL-C above 3 mmol/l). According to many large randomized trials and meta-analyses, there is evidence that statins which constitute the major class of lipid-lowering drugs are effective in the reduction of LDL-C in both primary and secondary prevention of cardiovascular events.https://www.med-sovet.pro/jour/article/view/1762coronary artery diseaseatherosclerosishyperlipidemialow-density lipoprotein cholesterolevolokumab |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
M. V. Ezhov |
spellingShingle |
M. V. Ezhov Recent progress in the management of atherosclerosis and hyperlipidemia Медицинский совет coronary artery disease atherosclerosis hyperlipidemia low-density lipoprotein cholesterol evolokumab |
author_facet |
M. V. Ezhov |
author_sort |
M. V. Ezhov |
title |
Recent progress in the management of atherosclerosis and hyperlipidemia |
title_short |
Recent progress in the management of atherosclerosis and hyperlipidemia |
title_full |
Recent progress in the management of atherosclerosis and hyperlipidemia |
title_fullStr |
Recent progress in the management of atherosclerosis and hyperlipidemia |
title_full_unstemmed |
Recent progress in the management of atherosclerosis and hyperlipidemia |
title_sort |
recent progress in the management of atherosclerosis and hyperlipidemia |
publisher |
Remedium Group LLC |
series |
Медицинский совет |
issn |
2079-701X 2658-5790 |
publishDate |
2017-12-01 |
description |
Despite the positive trend over the last decade, mortality from the circulatory system diseases in the Russian Federation remains high: in 2016, 616 cases per 100 thousand people were registered, with an absolute loss of about 900 thousand people, of whom nearly 50% died from coronary artery disease (CAD). Atherosclerosis plays a critical role in the development of cardiovascular disease, as the damage to the arterial bed begins early - already at a young age. The major modifiable risk factors for atherosclerosis are hyperlipidemia, hypertension, diabetes, smoking. The leading risk factor for coronary atherosclerosis is lowdensity lipoprotein cholesterol (LDL-C). According to EUROASPIRE III, in Russia, hypercholesterolemia is found in 65% of patients with CAD (LDL-C above 3 mmol/l). According to many large randomized trials and meta-analyses, there is evidence that statins which constitute the major class of lipid-lowering drugs are effective in the reduction of LDL-C in both primary and secondary prevention of cardiovascular events. |
topic |
coronary artery disease atherosclerosis hyperlipidemia low-density lipoprotein cholesterol evolokumab |
url |
https://www.med-sovet.pro/jour/article/view/1762 |
work_keys_str_mv |
AT mvezhov recentprogressinthemanagementofatherosclerosisandhyperlipidemia |
_version_ |
1721274116215930880 |